A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
- Status
- WITHDRAWN
- Phase
- PHASE3
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
- Status
- TERMINATED
- Phase
- PHASE1
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Status
- COMPLETED
- Phase
- N/A
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
- Status
- RECRUITING
- Phase
- PHASE4
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
- Status
- RECRUITING
- Phase
- PHASE2
First in Human Study of AZD9592 in Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2